Mark Murray

President, Chief Executive Officer

Dr Murray has served as Tekmira's President, Chief Executive Officer and Director since May 2008, when Dr Murray joined Tekmira in connection with the closing of the business combination between Tekmira and Protiva.

He previously was the President and CEO and founder of Protiva since its inception in the summer of 2000. Dr Murray has over 20 years of experience in both the R&D and business development and management facets of the biotechnology industry.

Dr Murray has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry Dr Murray has successfully completed numerous and varied partnering deals, directed successful product development programs, been responsible for strategic planning programs, raised over $30 million in venture capital and executed extensive business development initiatives in the U.S., Europe and Asia.

During his R&D career, Dr Murray worked extensively on three programs that resulted in FDA approved drugs, including the first growth factor protein approved for human use, a program he led for several years following his discovery.

Dr Murray obtained his Ph.D. in Biochemistry from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.

Back to top